The PE Ratio as of December 2024 (TTM) for Immuneering Corporation (IMRX) is -1.12

According to Immuneering Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -1.12. This represents a change of -34.75% compared to the average of -1.72 of the last 4 quarters.

Immuneering Corporation (IMRX) Historical PE Ratio (quarterly & annually)

How has IMRX PE Ratio performed in the past?

The mean historical PE Ratio of Immuneering Corporation over the last ten years is -20.24. The current -1.12 PE Ratio has changed 453.31% with respect to the historical average. Over the past ten years (40 quarters), IMRX's PE Ratio was at its highest in in the March 2023 quarter at 0.06. The PE Ratio was at its lowest in in the March 2020 quarter at -18.56.

Immuneering Corporation (IMRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Immuneering Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immuneering Corporation (IMRX) Average PE Ratio

How has IMRX PE Ratio performed in the past?

The current PE Ratio of Immuneering Corporation (IMRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immuneering Corporation (IMRX) PE Ratio vs. Peers

How is IMRX’s PE Ratio compared to its peers?

Immuneering Corporation’s PE Ratio is greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than PMV Pharmaceuticals, Inc. (-1.51), greater than Cullinan Oncology, Inc. (-4.82), greater than Enliven Therapeutics, Inc. (-13.27), greater than Larimar Therapeutics, Inc. (-3.90), greater than Centessa Pharmaceuticals plc (-12.61), greater than Celcuity Inc. (-5.65), greater than Ikena Oncology, Inc. (-1.35), greater than Replimune Group, Inc. (-4.55), greater than Nuvectis Pharma, Inc. (-4.07), less than Lyra Therapeutics, Inc. (-0.12), less than Kronos Bio, Inc. (-0.67), greater than Gossamer Bio, Inc. (-2.71), greater than Monte Rosa Therapeutics, Inc. (-4.90), greater than NewAmsterdam Pharma Company N.V. (-13.31), less than Inventiva S.A. (-1.11), greater than Compass Therapeutics, Inc. (-4.35),

Build a custom stock screener for Immuneering Corporation (IMRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immuneering Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immuneering Corporation (IMRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immuneering Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.